5-MeO-DMT
5-MeO-DMT, an alkaloid. Very fast, very potent tryptamine psychedelic. A serotonergic agonist with affinity rank 5-HT1A >> 5-HT2A (5-HT1A… Intranasal half-life 0.5 h.
Very fast, very potent tryptamine psychedelic. A serotonergic agonist with affinity rank 5-HT1A >> 5-HT2A (5-HT1A is the primary high-affinity target, ~300-fold over 5-HT2A). O-demethylated by CYP2D6 to bufotenine and an MAO substrate. Found in Bufo alvarius (Sonoran toad) venom. Risks: extreme intensity, transient hypertension, rare serotonin toxicity when MAOI-combined.
ROUTES REORDERED so the dosing default is a solvable route. INH (vaporised) is the commonest real-world route and stays declared, but no human study reports an inhaled parameter for it, so it rendered a dose against no curve. IN is the route this record actually has PK for. PubChem CID 1832. PK: Rucker 2024 (PMID:38616411) verbatim "the mean terminal elimination half-life was <27 min" (Tmax ~8–10 min) for intranasal BPL-003 5-MeO-DMT benzoate; authored as 0.45 h. 5-HT2A occupancy not authored — 5-HT2A is the weak target (5-HT1A primary) and its Ki is table-only (see AUTHORING_GAPS).
Pharmacokinetics
- Intranasal — t½ 27 min
Sources: PMID:38616411